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Abstract 
Background: Progressive bone marrow fibrosis (BMF) is a cardinal feature of many myeloproliferative neoplasms 
(MPNs) and there is a documented association between the severity of BMF and overall prognosis. We conducted an 
exploratory analysis of sequential BMF data from two phase I studies of long-term treatment with the Janus kinase 2 
(JAK2) inhibitor fedratinib in patients with myelofibrosis.
Methods: Bone marrow samples were obtained at baseline and after every six cycles (24 weeks) of daily fedratinib 
treatment. Fibrosis was centrally assessed by three independent haematopathologists, who were blinded to the 
patients’ data, and graded according to European Consensus Myelofibrosis Grading Criteria. The analysis population 
comprised patients with a baseline BMF grade ≥1, and at least one post-baseline BMF grade assessment. Changes in 
BMF grade compared with baseline were classified as improvement (≥1 grade reduction), stabilisation (no change in 
any baseline BMF grade <3) or worsening (≥1 grade increase).
Results: Twenty-one patients were included in the analysis. A total of 153 bone marrow samples were analysed. 
Improvement or stabilisation of BMF from baseline was recorded in 15 of 18 (83 %) evaluable patients at cycle 6 and 
in four of nine (44 %) evaluable patients at cycle 30. Two patients achieved resolution of their BMF (grade = 0) by 
cycle 12.
Conclusions: This exploratory analysis indicates that improvement or even resolution of BMF may be achievable 
with JAK2 inhibitor therapy in some patients with MPNs and myelofibrosis.
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Background
Myelofibrosis is a feature of several Philadelphia-chro-
mosome negative myeloproliferative neoplasms (MPNs), 
such as primary myelofibrosis (PMF), essential throm-
bocythaemia (ET) and polycythaemia vera (PV) [1]. 
Myelofibrosis can either be present at baseline, as seen in 
patients with PMF, or develop upon disease progression 
in patients with ET and PV [2, 3]. This group of MPNs 
is frequently associated with Janus kinase (JAK)2 V617F, 
MPL W515 L/K or exon 9 CALR gene mutations that 
have been reported to activate JAK2/signal transducer 
and activator of transcription (STAT) signalling [4–9]. 
Clinically, the presence of myelofibrosis is associated 
with splenomegaly, peripheral blood cytopaenias and 
constitutional symptoms including fatigue, night sweats 
and fever [3, 10, 11]. Several studies have demonstrated 
associations between the degree of bone marrow fibrosis 
(BMF), as assessed by morphological analysis, periph-
eral blood count abnormalities, splenomegaly and overall 
prognosis in patients with myelofibrosis [12–16].
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The only potentially curative treatment for patients 
with myelofibrosis is allogeneic haematopoietic cell 
transplantation, which can result in a rapid reduction in 
BMF [17]. However, advanced age and co-morbidities 
preclude this as an option for most patients [18, 19]. 
Conventional clinical management has therefore focused 
on supportive therapies that palliate myelofibrosis symp-
toms, but appear to have no significant effect on BMF 
[12, 16]. Recent data from an open-label study and a case 
report suggest that long-term therapy with the JAK1/2 
inhibitor ruxolitinib may improve or stabilise the pro-
gression of BMF in a proportion of patients with myelofi-
brosis [20, 21].
Fedratinib (SAR302503; TG101348) is a JAK2-selective 
inhibitor that was developed as a treatment for MPNs 
based on pre-clinical data that showed it caused a reduc-
tion in JAK2 mutant allele burden and BMF in murine 
models of myeloproliferative disease [22, 23]. Clini-
cal evaluation of fedratinib began in 2008 and results 
of phase I–III studies demonstrated clinical benefit as 
evidenced by reductions in splenomegaly and symptom 
burden in patients with myelofibrosis [24–26]. The clini-
cal evaluation of fedratinib also included prospective 
assessment of the effects of long-term JAK2 inhibition 
on BMF status. Although clinical development of fed-
ratinib was discontinued in November 2013 (due to a few 
reports of treatment-emergent encephalopathy, resem-
bling Wernicke’s), the effects of JAK2 inhibition on BMF 
may be relevant for predicting the long-term efficacy of 
other JAK2 inhibitors. We therefore report the results 
of an exploratory analysis of sequential BMF data from 




Patients with PMF, post-ET MF and post-PV MF par-
ticipated in a phase I dose-escalation study (TED12037; 
Clinicaltrials.gov identifier: NCT00631462) of daily 
oral fedratinib [24] and its long-term extension study 
TED12015 (NCT00724334). Patients were eligible for 
entry into TED12015 if they had tolerated fedratinib 
therapy and had achieved clinical benefit, defined as sta-
ble disease, clinical improvement, partial remission or 
complete remission in accordance with the International 
Working Group for Myelofibrosis Research and Treat-
ment (IWG-MRT) response criteria [27, 28], following 
six 4-week cycles of fedratinib in TED12037. Patients 
entered TED12015 immediately upon completion of 
TED12037, with no gap in treatment, and continued on 
the same daily dose of fedratinib in consecutive 4-week 
cycles. Patients were permitted to remain on treatment 
for as long as they continued to derive clinical benefit. 
Treatment was discontinued in the event of symptomatic 
or disease progression, unacceptable toxicity, or patient 
non-compliance/withdrawal of consent. In the absence of 
disease progression or unacceptable toxicity, the dose of 
fedratinib could be escalated up to the maximum toler-
ated dose of 680 mg/day.
Assessment of bone marrow fibrosis
Bone marrow trephine biopsies were obtained at baseline 
and after six cycles (24 weeks) of treatment in TED12037. 
Repeat biopsies continued to be obtained every six cycles 
for the duration of TED12015. Biopsy sections were 
stained with haematoxylin and eosin, reticulin and Mas-
son’s trichrome in order to allow grading of BMF on a 
scale from 0 to 3 using the European Consensus Myelofi-
brosis Grading Criteria. A description of the grading sys-
tem is shown in Table 1 [29]. Staining was performed by 
the local laboratory at each of the six study sites.
Stained sections were analysed and graded centrally by 
three independent haematopathologists using a prede-
fined charter. Reviewers were blinded to subject demo-
graphics (except for patient age and gender), treatment 
time point, clinical response, clinical history and the 
local pathology results. A consensus on fibrosis grading 
required agreement by at least two pathologists; if all 
three reviewers disagreed discrepancies were resolved 
by open discussion followed by a consensus fibrosis 
score. All bone marrow samples were from patients with 
a baseline BMF grade of ≥1 in TED12037 and with at 
least one post-baseline BMF grade assessment (in either 
study). Changes in BMF grade, after every six cycles of 
Table 1 Grading criteria for bone marrow fibrosis [29]
Bone marrow fibrosis is assessed in areas of haematopoietic cellularity
Grading Description
0 Scattered linear reticulin with no intersections corresponding to normal bone marrow
1 Loose network of reticulin with many intersections, especially in perivascular areas
2 Diffuse and dense increase in reticulin with extensive intersections, occasionally with only  
focal bundles of collagen and/or focal osteosclerosis
3 Diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, 
often associated with significant osteosclerosis
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treatment, were compared with the TED12037 baseline 
and classified as: improvement (≥1 grade reduction), sta-
bilisation (no change in any baseline grade <3), persistent 
grade 3, or worsening (≥1 grade increase).
Other clinical assessments
Splenomegaly was assessed by palpation (cm below the 
left costal margin) during physical examination, at base-
line and every subsequent treatment cycle. Haematology 
parameters (including haemoglobin and white blood cell 
[WBC] count) were also assessed at baseline and every 
subsequent cycle.
Role of the funding source
The study sponsor participated in the design of the clini-
cal studies and in the collection of the fibrosis data. The 
sponsor played no role in the interpretation of the fibro-
sis data presented in this paper. The sponsor funded 
medical writing assistance and reviewed the final draft 
for study-parameter related accuracy. The final decision 
to publish the paper was made solely by the authors.
Results
Patients
Of the 59 patients who were treated with fedratinib in 
TED12037, 15 patients discontinued treatment before the 
completion of six cycles (due to AEs [n  =  6], investiga-
tor decision/intercurrent illness [n = 3], or withdrawal of 
consent [n = 6]). One additional patient opted not to enter 
the extension phase study. Therefore, 43 of the 59 patients 
(73 %) enrolled in TED12015 and continued on fedratinib 
treatment. Twenty-one (36  %) of these patients were eli-
gible for inclusion in the BMF assessment. The main rea-
sons for exclusion from the BMF assessment were missing 
baseline samples and absence of documented patient con-
sent. Demographics and baseline disease characteristics of 
the BMF analysis population (n = 21) and the all-treated 
population (n = 43) at entry into TED12037 are shown in 
Table  2. There were only minor differences between the 
baseline characteristics of the all-treated and BMF analy-
sis populations. Demographic data for the 59 patients who 
started in TED12037 have been published previously [24].
Patients were receiving fedratinib doses ranging from 
120 to 680 mg/day at the end of TED12037 and contin-
ued on these doses upon entry to TED12015. The overall 
median fedratinib dose across both studies was 489.6 mg/
day (range 144.5–682.7) and the median treatment dura-
tion was 35 cycles (range 7–61).
Bone marrow fibrosis
A total of 153 bone marrow samples were analysed 
(including post-baseline samples from patients excluded 
from the BMF population due to missing baseline 
data), of which 87 samples were included in the analysis 
reported herein. A consensus on BMF grade was reached 
without discussion for 150 (98  %) of the samples, with 
agreement among all three haematopathologists for 118 
(77 %) and between two pathologists for 32 (21 %) of the 
samples. BMF grade for the remaining three samples 
(2 %) was assigned following open discussion, in accord-
ance with the central pathology review charter. Changes 
in BMF grade from baseline for each patient in the BMF 
population are summarised in Table 3. Figure 1 illustrates 
the proportion of patients with improvement, stabilisa-
tion or worsening of BMF according to treatment cycle. 
Because of the small numbers of patients at later time 
points, proportional data are presented up to cycle 30. Of 
the nine patients evaluable at cycle 30, four (44  %) had 
shown an improvement in BMF grade and four (44  %) 
had shown no change in BMF grade. Two of the patients 
with BMF improvement at cycle 30 had a two-grade 
fibrosis reduction from their respective baselines.
Changes in BMF according to the baseline character-
istics and overall clinical response of individual patients 
are listed in additional file  1: Table S1. In some cases, 
improvements in BMF coincided with a reduction in 
palpable splenomegaly with fedratinib dosing beyond 
cycle 6. Many patients in the BMF analysis population 
achieved either stable disease or clinical improvement, as 
assessed by the IMWG-MRT criteria.
Two patients had achieved complete resolution of 
fibrosis (BMF grade 0) by treatment cycle 12. Patient 1, 
with post-PV MF, presented with a spleen size of 13 cm 
and BMF grade of 2 at baseline. Patient 2, with PMF, 
presented with a spleen size of 4  cm and BMF grade 1 
at baseline. Patient 1 achieved complete clinical remis-
sion, according to IWG-MRT response criteria, starting 
at cycle 24 and continuing to cycle 40. Figure  2 shows 
representative images for Patient 1 at different treatment 
cycles. In both patients, white blood cell counts normal-
ised during treatment and a reduction in spleen size of up 
to 100  % was recorded. Haemoglobin levels normalised 
in patient 1 and improved in patient 2. Haematological 
and clinical assessments for these two patients are shown 
in Fig. 3. Scatter plots depicting the distribution of WBC 
levels, spleen size changes, and haemoglobin levels in 
individual patients at each treatment cycle based on BMF 
status are shown in additional file 2: Figure S1.
Discussion
Identification of the high frequency of activating muta-
tions affecting JAK/STAT signalling in patients with 
Ph-negative (Ph−) MPNs has established dysregula-
tion of the JAK/STAT signalling pathway as the major 
contributor to the pathogenesis of haematopoietic stem 
and progenitor cell derived MPNs [3]. In patients with 
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MPNs, aberrant signalling from the neoplastic haemat-
opoietic clone results in increased levels of inflammatory 
and angiogenic cytokines, as well as fibrotic changes in 
the bone marrow stroma, causing the clinical signs and 
symptoms seen in myelofibrosis [1, 30]. A direct causal 
role for enhanced JAK2 signaling in bone marrow fibro-
sis has been demonstrated in mice transplanted with 
JAK2V617F+ bone marrow cells [23]. The underlying 
pathogenic mechanisms in MPNs still require further 
elucidation; however, our current understanding sup-
ports the rationale for inhibition of JAK signalling with 
anti-JAK1 and anti-JAK2 agents that could potentially 
inhibit the inflammatory signalling cascade, preventing 
or reducing BMF in patients with Ph− MPNs.
The results of this exploratory analysis support this 
hypothesis by demonstrating that prolonged treat-
ment with the JAK2 inhibitor, fedratinib, was associated 
with stabilisation or improvement of BMF in a propor-
tion of patients with PMF, post-ET myelofibrosis and 
post-PV myelofibrosis. These findings are in agreement 
with recently published data from studies of ruxolitinib 
therapy, which also suggested that JAK inhibition may 
prevent the progression of BMF in some patients with 
MPNs with myelofibrosis [20, 21]. Although the small 
number of patients studied precluded statistical compari-
sons, the results suggest that improvement in BMF may 
be associated with concomitant improvements in sple-
nomegaly and peripheral blood counts in some patients. 
Table 2 Baseline characteristics of BMF analysis and all-treated populations at entry into TED12037
Percentages may not sum to 100 due to rounding
a One patient had a baseline BMF reading but no subsequent BMF readings and was therefore excluded from the BMF population
b Twenty-one patients had missing baseline BMF data
Characteristic BMF analysis population (n = 21) All-treated population (n = 43)
Mean age, years (SD) 63.5 (10.7) 63.8 (10)
Sex, n (%)
 Male 12 (57) 26 (60)
 Female 9 (43) 17 (40)
Disease subtype, n (%)
 PMF 12 (57) 30 (70)
 Post-ET MF 1 (5) 2 (5)
 Post-PV MF 8 (38) 11 (26)
Risk status [27], n (%)
 High 8 (38) 15 (35)
 Intermediate 13 (62) 28 (65)
JAK2V617F mutation status, n (%)
 Positive 19 (90) 39 (91)
 Negative 2 (10) 4 (9)
Last fedratinib dose in TED12037, mg/day
 120 3 (14) 3 (7)
 240 2 (10) 4 (9)
 360 1 (5) 5 (12)
 400 0 1 (2)
 440 2 (10) 4 (9)
 520 7 (33) 11 (26)
 600 1 (5) 3 (7)
 680 5 (24) 12 (28)
BMF grade, n (%)
 0 0 (0) 0 (0)
 1 2 (10) 2 (5)
 2 10 (48) 10 (23)
 3 9 (43) 10 (23)a,b
Spleen size (cm), median (range) 18 (4–34) 18 (4–34)
Haemoglobin (g/dL), median (range) 9.7 (7.4–15.2) 9.3 (7.3–15.2)
White blood cells (×109/L), median (range) 16.4 (2.1–103.3) 14.9 (2.1–103.3)
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The generalizability of our results is clearly limited by the 
small sample size and by the inherent bias associated with 
focusing the analyses on patients who were responding to 
long-term fedratinib treatment (15 of the 59 patients who 
began the phase 1 study discontinued treatment early).
In this era of disease-modifying agents, such as JAK2 
and JAK1/JAK2 inhibitors, accurate grading of BMF 
has become crucial not only for the precise diagnosis 
of MPNs, but also for assessment of response to treat-
ment. This study used the BMF grading system advocated 
by the World Health Organization 2008 classification, 
which is based on semi-quantitative assessment of reti-
culin stain on a 4-grade scale (from 0 to 3) (2008 WHO 
Classification of Tumors of Hematopoietic and Lymphoid 
Tissue) [14]. This study showed a high level of agreement 
on reticulin fibrosis grading among the three pathologists 
(98 %), when using this system [31]. However, these crite-
ria do have limitations, in particular when evaluating the 
dynamic changes of BMF associated with greater tissue 
heterogeneity following treatment with disease-modi-
fying agents; further study is needed to optimise BMF 
grading in the setting of this post-treatment heteroge-
neity, which is not addressed in the current WHO grad-
ing system [31]. Despite these limitations, use of BMF 
grading has previously been demonstrated to have diag-
nostic and prognostic value in patients with Ph− MPNs 
[13–15], and it is therefore important that the effects of 
novel therapies on BMF are adequately investigated and 
reported.
Current practice in the management of myelofibrosis 
is to use a range of clinical and demographic parameters 
to risk-categorise patients [32]. Recent studies suggest 




BMF grade Change in BMF 
grade from base-




Cycle 6  
(n = 18)
Cycle 12  
(n = 16)
Cycle 18  
(n = 14)
Cycle 24  
(n = 9)
Cycle 30  
(n = 9)
PMF 3 2 n/a n/a n/a n/a Improved
PMF 3 2 1 1 n/a 1 Improved
PMF 3 3 n/a 3 n/a n/a Persistent grade 3
PMF 3 3 n/a n/a n/a n/a Persistent grade 3
PMF 3 2 3 n/a 2 2 Improved
PMF 3 2 2 2 2 n/a Improved
PMF 2 3 3 n/a n/a n/a Worsened
PMF 2 2 2 2 n/a n/a Stabilised
PMF 2 n/a 3 n/a n/a n/a Worsened
PMF 2 n/a 3 n/a n/a n/a Worsened
PMF 1 1 2 1 1 1 Stabilised
PMF 1 n/a 0 0 0 n/a Improved
Post-PV MF 3 2 2 3 n/a n/a Persistent grade 3
Post-PV MF 3 3 n/a 3 3 3 Persistent grade 3
Post-PV MF 3 2 3 3 3 n/a Persistent grade 3
Post-PV MF 2 3 2 2 n/a 2 Stabilised
Post-PV MF 2 1 0 0 n/a 0 Improved
Post-PV MF 2 3 3 3 2 3 Worsened
Post-PV MF 2 2 3 n/a 2 2 Stabilised
Post-PV MF 2 2 2 2 1 1 Improved








































Fig. 1 Summary of bone marrow fibrosis changes from baseline, by 
treatment cycle (*Persistent grade 3)
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that the addition of BMF grading to the International 
Prognostic Scoring System improves prognostication 
of patients with PMF [14]. Patients with PV and fibrosis 
at presentation are less prone to experience thrombosis 
during their clinical course and more prone to develop 
post-PV MF [33]. These results, in conjunction with our 
analysis, add support to the importance of including 
BMF assessment at presentation and during the treat-
ment of patients with myelofibrosis.
Conclusion
These findings with a JAK2 selective inhibitor, fedratinib, 
together with the previously reported effects of the JAK1/
JAK2 inhibitor ruxolitinib, indicate that improvement or 
even resolution of BMF in some patients with myelofi-
brosis may be achievable with JAK2 inhibitor therapy.
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